At the 7th Annual Legal Media Group (LMG) Life Sciences Awards on September 18, 2019, partner R. Danny Huntington and the firm were recognized and awarded for their achievements over the past year. Danny was presented as winner of the Patent Strategy & Management Attorney of the Year in the District of Columbia for 2019, and the firm was presented as a winner of a Hatch-Waxman Impact Case of the Year for its work representing Pfizer and Synthon in the Teva Pharmaceuticals et al v. Sandoz et al. (Fed. Circ. 2018) case.
“The firm congratulates Danny on this tremendous, and much deserved, honor. Danny is strategic, thorough, and extremely knowledgeable about all phases of intellectual property law and the life sciences sector,” said E. Anthony Figg, member and co-founder of the firm. “Additionally, we are incredibly proud of the hard work we put into Teva Pharmaceuticals et al v. Sandoz et al, and having the case recognized by LMG is exceptionally rewarding. What we achieved for our clients Pfizer and Synthon is a great representation of the amazing talent and zeal of our lawyers.”
Danny is involved in all phases of intellectual property law, including United States and foreign patent prosecution, litigation in the Federal and State Courts, licensing, and general client counseling. He has extensive patent interference experience, with particular expertise in biotechnology and pharmaceuticals, and has been involved in inter partes review (IPR), post grant review (PGR), and covered business method (CBM) proceedings. Danny is a member of the American Bar Association (ABA), the Federal Circuit Bar Association (FCBA), the American Intellectual Property Law Association (AIPLA) and its Patent Trial and Appeal Board (PTAB) Trial Committee, and the Intellectual Property Owners Association. He is also a member of the Fédération Internationale des Conseils en Propriété Intellectuelle (FICPI), of which he is a president of honour and a member of the Biotechnology Committee.
The Teva case was a hard-fought Hatch-Waxman case that involved four patents directed to a dosing regimen for the drug, glatiramer, for the treatment of a form of multiple sclerosis. Rothwell Figg represented defendants, Synthon Pharmaceuticals and Pfizer, in both a bench trial in federal court in Delaware and in the appeal to the Court of Appeals for the Federal Circuit. The asserted patent claims were held invalid by the Delaware court, and that decision was affirmed on appeal. The decisions paved the way for Synthon and Pfizer to obtain approval from the FDA for their glatiramer products. The Rothwell Figg team was comprised of E. Anthony Figg, Sharon Davis, Jennifer Nock, Brett Postal, and other attorneys and paralegals.
The LMG Life Sciences Awards provide an unrivaled opportunity for the leading firms and their clients from around the world to come together as the firms, individuals, and companies behind the most innovative and challenging life sciences work of the past year are recognized. The event, which is part of the 2019 research cycle for LMG Life Sciences, presented categories that recognize work in the four main practice areas covered by the guide, including regulatory, intellectual property, financial & corporate, and litigation & enforcement. To learn more about the event and the awards, please click here.
